2024-518033-28-00招募中4 期
Multicentre, open-label, randomised, two-arm, parallel-group, superiority study to assess bioavailability and practicability of Envarsus® compared with Advagraf® in de novo liver transplant recipients
Universitaetsklinikum Regensburg AöR15 个研究点 分布在 1 个国家目标入组 268 人开始时间: 2024年10月31日最近更新:
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 招募中
- 发起方
- 入组人数
- 268
- 试验地点
- 15
- 主要终点
- Dose-normalised trough level (C/D ratio) measured at 12 weeks
研究概览
简要总结
To compare the bioavailability of two once-daily tacrolimus formulations in de novo liver transplant recipients and show superiority of Envarsus® versus Advagraf® in terms of C/D (concentration/dose) ratio after 12 weeks of therapy. The recently identified and postulated parameter C/D ratio is used as an estimate of tacrolimus bioavailability.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 否
入选标准
- •Signed and dated written informed consent
- •Adult (≥18 years old) male or female
- •Recipient of a whole liver transplant from a deceased donor or a split liver transplant from a deceased or living donor
- •ABO blood type compatible with the organ donor
- •Able to swallow an oral formulation of tacrolimus in tablet or capsule form
排除标准
- •Multi-organ transplantation
- •Ongoing, planned or foreseeable use of cyclosporine or any tacrolimus preparation other than Envarsus® or Advagraf® (except for immediate-release formulations administered before randomisation)
- •Any prolonged-release tacrolimus treatment prior to randomisation
- •Pregnant or nursing (lactating) female, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test
- •Female of child-bearing potential, defined as physiologically capable of becoming pregnant, unless using a reliable method* of contraception
- •Participation in another interventional clinical trial during the time period from randomisation to study end, if the trial is testing an IMP (AMG study**) or if the intervention and/or follow-up requirements of the trial impede or interfere with either the objectives of EnGraft or the treatment / follow-up requirements of EnGraft
- •Any condition or factor which, in the judgement of the investigator, would place the subject at undue risk, invalidate communication with the investigator or study team, or hamper compliance with the trial protocol or follow-up schedule
- •Inability to freely give informed consent (e.g. individuals under legal guardianship)
- •Any previous organ allograft transplantation
- •Biopsy-proven acute rejection that is ongoing at the time of randomisation
- •Occurrence of post-transplant thrombosis, occlusion or stent placement in any major hepatic arteries, hepatic veins, portal vein or inferior vena cava
- •History of extra-hepatic malignancy that could not be curatively treated
- •Hepatocellular carcinoma with extra-hepatic spread or macrovascular invasion
- •Uncontrolled systemic infection
- •Requirement of life support measures such as ventilation or vasopressor agents (>20 μg/kg BW/h) at the time of randomisation
- •Known contraindication or hypersensitivity to tacrolimus, and/or to any of the excipients listed in section 6.1 of the Summary of Product Characteristics (SmPC) of both Envarsus® and Advagraf®, and/or to any other macrolides
结局指标
主要结局
Dose-normalised trough level (C/D ratio) measured at 12 weeks
Dose-normalised trough level (C/D ratio) measured at 12 weeks
次要结局
- Infections (HCV, HBV, CMV, EBV) at 1, 2 and 3 years
- Degree of liver fibrosis (fibroscan4 or biopsy) at 12 weeks and 1, 2, 3 years
- Number of IMP dose adjustments until 12 weeks
- Time to reach the first defined range in target trough level
- Number of measurements above and below the first defined range in target trough level
- Dose-normalised trough level (C/D ratio) measured at 1, 2 and 3 years
- Mean tacrolimus trough level and inter-patient variability (range) of tacrolimus trough levels at 1, 2, 4 and 12 weeks
- Inter-patient variability (range) of tacrolimus total daily dose until 12 weeks
- Proportion of patients with trough levels lower, within, or higher than the standard reference range at 1, 2, 4 and 12 weeks
- Incidence and severity (BANFF criteria) of clinically-confirmed BPAR2 at 12 weeks and 1, 2, 3 years
- Incidence of graft failure (defined as necessity for re-transplantation) at 12 weeks and 1, 2, 3 years
- Incidence of death (for any reason) at 12 weeks and 1, 2, 3 years
- Treatment failure rate (composite endpoint of BPAR, graft failure or death) at 12 weeks and 1, 2, 3 years
- Time to treatment failure (composite endpoint of BPAR, graft failure3 or death) after randomisation
- Incidence of acute rejections requiring treatment at 12 weeks
- Incidence of multiple rejection episodes at 12 weeks
- Laboratory measures at 12 weeks and 1, 2, 3 years: liver function, metabolic profile, renal function
- Malignancies at 1, 2 and 3 years
- Incidence, type, severity, seriousness and causality of adverse events (AEs)
- Change vs. baseline in vital signs (heart rate, blood pressure) and body weight
- Incidence of de novo occurrence of tremor or vision impairments
- Incidence of post-transplant diabetes mellitus and post-transplant hyperglycaemia at 12 weeks and 1, 2, 3 years
- Dose-normalised trough level (C/D ratio) 12 weeks after transplantation
- Number and doses of immunosuppressive medications (incl. other tacrolimus formulations) at 12 weeks and after 12 weeks (if applicable)
- Recurrence of primary hepatic disease
- Incidence of DSA up to 12 weeks and at 1, 2 and 3 years (optional)
- Continuation rate at 12 weeks
- Incidence and time to study treatment discontinuation
- Incidence, time to and reason for patient withdrawal from study
研究者
coTrial Associates
Scientific
Universitaetsklinikum Regensburg AöR
研究点 (15)
Loading locations...
相似试验
招募中
1 期
Multicentre, open-label, randomised, two-arm, parallel-group, superiority trial to assess bioavailability and practicability of two once-daily tacrolimus formulations, Envarsus® compared with Advagraf™, administered in kidney transplant recipientsProphylaxis of transplant rejection in adult kidney allograft recipientsMedDRA version: 21.1Level: LLTClassification code: 10050436Term: Prophylaxis against renal transplant rejection Class: 10042613CTIS2023-503531-18-00niversitaetsklinikum Regensburg300
进行中（未招募）
2 期
Clinical trial to Evaluate Treatment Compliance, Efficacy and Safety of an Improved new formulation of Deferasirox in the form of Granules in children of the age 2 to 18 Years Old who have Iron overload.CTRI/2017/10/010252ovartis Healthcare Private Limited6
进行中（未招募）
不适用
A randomized, multicenter, open-label, two-arm, parallel, phase III study to evaluate the efficacy and safety of nicotinic acid administered in combination with simvastatin for 6 months in comparison to simvastatin therapy alone in inhibiting the progression of atherosclerosis in patients with carotid arteries stenosis and dyslipidemia.EUCTR2014-003213-29-PLSciencePharma spólka z ograniczona odpowiedzialnoscia sp. j.
进行中（未招募）
1 期
Pharmacokinetics, pharmacodynamics and safety of DEB025/alisporivir in combination with ribavirin therapy in chronic hepatitis C genotype 2 and 3 patients who have previously failed interferon therapy or are intolerant or unable to take interferoChronic hepatitis CMedDRA version: 18.0Level: PTClassification code 10008912Term: Chronic hepatitis CSystem Organ Class: 10021881 - Infections and infestationsEUCTR2013-003751-38-FRovartis Pharma Services AG52
进行中（未招募）
不适用
A study to evaluate the efficacy and safety of bevacizumab in combination with trastuzumab/docetaxel in patients with breast cancer that spread to other tissues.First-line treatment of patients with HER2 negative metastatic breast cancer.MedDRA version: 14.1Level: LLTClassification code 10027475Term: Metastatic breast cancerSystem Organ Class: 100000004864EUCTR2006-001365-42-ATF. Hoffmann-La Roche Ltd424